Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154077 | 0.83 | POLB (1.00) | POLBKDM4EPKMALDH1A1MAPK1 | |
| SCHEMBL12793323 | 0.82 | KDM4E (0.79) | POLBKDM4EPKMALDH1A1MAPK1 | |
| SCHEMBL12386397 | 0.81 | KDM4E (0.77) | POLBKDM4EPKMALDH1A1MAPK1 | |
| SCHEMBL2080837 | 0.81 | KDM4E (0.77) | POLBKDM4EPKMALDH1A1MAPK1 | |
| SCHEMBL4009309 | 0.81 | KDM4E (0.77) | POLBKDM4EPKMALDH1A1MAPK1 | |
| SCHEMBL2831202 | 0.81 | KDM4E (0.77) | POLBKDM4EPKMALDH1A1MAPK1 | |
| SCHEMBL4009686 | 0.81 | CYP2D6 (0.49) | POLBKDM4EPKMALDH1A1MAPK1 | |
| SCHEMBL5306415 | 0.81 | POLB (1.00) | POLBKDM4EPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL144421 | 0.80 | POLB (0.67) | POLBKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL289460 | 0.78 | USP2 (0.62) | POLBPKMALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494994-B2 | Phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1721897-A1 | Phenylpyridinylpiperazin derivatives, the process to make them and the pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | POLB 4224/4885KDM4E 2057/4885PKM 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.